Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities

Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Transfusion (Impact Factor: 3.57). 09/2006; 46(8):1279-85. DOI: 10.1111/j.1537-2995.2006.00891.x
Source: PubMed

ABSTRACT Fresh-frozen plasma (FFP) is frequently transfused to patients with mild prolongation of coagulation values under the assumption that FFP will correct the coagulopathy. There is little evidence to support this practice, however. To determine the effect of FFP on coagulation variables and correlation with bleeding in patients with mildly prolonged coagulation values, a prospective audit of all FFP transfusions at the Massachusetts General Hospital between September 2, 2004, and September 30, 2005, was performed.
All patients transfused with FFP for a pretransfusion prothrombin time (PT) between 13.1 and 17 seconds (international normalized ratio [INR], 1.1-1.85) and with a follow-up PT-INR within 8 hours of transfusion were included. Of 1091 units of FFP transfused, follow-up coagulation values within 8 hours were available for 121 patients (324 units).
Transfusion of FFP resulted in normalization of PT-INR values in 0.8 percent of patients (95% confidence interval [CI], 0.0020-0.045) and decreased the PT-INR value halfway to normalization in 15.0 percent of patients (95% CI, 0.097-0.225). Median decrease in PT was 0.20 seconds (median decrease in INR, 0.07). Pretransfusion PT-INR, partial thromboplastin time, platelet count, and creatinine values had no correlation with red blood cell loss.
It is concluded that transfusion of FFP for mild abnormalities of coagulation values results in partial normalization of PT in a minority of patients and fails to correct the PT in 99 percent of patients.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve hemostasis in the perioperative setting as alternatives to allogeneic blood products remains controversial. To examine the efficacy and safety of PCCs and FIBCs, we conducted a systematic review-in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement-to compare the use of these transfusion alternatives in bleeding surgical patients. We performed a literature search of English articles published between July 1997 and July 2012 in MEDLINE via PubMed, The Cochrane Library, and CINAHL. Five randomized trials and 15 nonrandomized studies with a comparator group were included in the final review. Studies were sorted into 1 of the following 3 clinical settings: cardiac surgery, non-cardiac surgery, and reversal of warfarin anticoagulation. Risk of bias was assessed using the Cochrane risk of bias tool. With the exception of 2 randomized controlled trials, the existing body of literature on the use of PCCs and FIBCs in the perioperative setting was assessed to have a high degree of methodological bias. Overall, prospective studies in the cardiac surgery grouping suggested that patients receiving FIBC and/or PCCs required less allogeneic blood transfusion and had less chest tube drainage. In studies of warfarin reversal, PCCs more rapidly corrected the International Normalized Ratio compared to plasma; however, in the setting of intracranial hemorrhage, functional outcomes were poor regardless of the reversal strategy. With regards to safety outcomes, reporting was not uniform and raises concerns of underreporting. Adequately powered, methodologically sound trials would be required for more definitive conclusions to be drawn about the efficacy of PCCs and FIBC over conventional blood components for the treatment of perioperative coagulopathy in bleeding patients.
    Transfusion medicine reviews 02/2013; DOI:10.1016/j.tmrv.2013.01.002 · 4.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic blood transfusion increases the incidence of tumor recurrence and affects survival of patients undergoing liver resection. Acute normovolemic heamodilution (ANH) helps to decrease the exposure to allogeneic transfusion. This technique in cirrhotic patients undergoing major liver resection may compromise the coagulation process. Study of coagulation effects of ANH using rotation thromboelastometry (ROTEM), which provides global evaluation of coagulation function, may add beneficial effects.
    01/2013; 29(1):53-60. DOI:10.1016/j.egja.2012.08.004
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coagulopathy is associated with massive haemorrhage and is an independent predictor of death. The causes and mechanisms are multiple: clotting factors and platelets consumption, loss and dilution, acidemia, shock, hypothermia, hypocalcemia, activation of fibrinolytic pathways, as well as antithrombotic therapy. Coagulopathy management has changed recently. Fresh frozern plasma and platelets should be given early and more often to injured patients requiring massive transfusion. The place of adjunctive hemostatic therapy is discussed. Fibrinogen concentrates are indicated if significant bleeding is accompanied by a low plasma fibrinogen level. Prothrombin complex concentrate is the leading treatment of haemorrhagic complications associated with vitamin K antagonists, but is not recommended in other massive haemorrhage. Tranexamic acid reduced the risk of death in bleeding trauma patients.
    Le Praticien en Anesthésie Réanimation 02/2011; 15(1):19-25. DOI:10.1016/j.pratan.2010.12.006


1 Download
Available from